About the Authors
- Don B. Gammon
-
Affiliation Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada
- Branawan Gowrishankar
-
Affiliation Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada
- Sophie Duraffour
-
Affiliation Laboratory of Virology and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
- Graciela Andrei
-
Affiliation Laboratory of Virology and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
- Chris Upton
-
Affiliation Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
- David H. Evans
-
* E-mail: devans@ualberta.ca
Affiliation Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada
Competing Interests
Financial competing interest: A provisional U.S. patent application (No. 61/224,694) has been submitted by DBG and DHE entitled “Oncolytic Viruses and Methods for Treating Neoplastic Disorders” for the use of poxviruses deficient in ribonucleotide reductase genes as oncolytic agents.
Author Contributions
Conceived and designed the experiments: DBG DHE. Performed the experiments: DBG BG SD GA CU. Analyzed the data: DBG BG SD GA CU DHE. Wrote the paper: DBG DHE.